ClinicalTrials.gg
RecruitingNCT07254793Updated Oct 29, 2026

Prophylactic DLI-X for Leukemia Relapse After HCT

A Phase 1 interventional study of Exercise Mobilized Prophylactic DLI and Standard Prophylactic DLI in Acute Lymphoid Leukemia, Acute Myeloid Leukemia and Acute Undifferentiated Leukemia (AUL), sponsored by University of Arizona. Recruiting at 1 site in United States. Open to participants aged Up to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by University of Arizona · Phase 1, Interventional, and Treatment

How we know

Updated Oct 29, 2026Now RecruitingSite recruiting status changed+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
Up to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 168 open to participants now, 274 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.

Planned enrollment
114th of 1,269
180 · median 35
Started
2026
with 38 others
Phase 1
500 of 1,545
47 open now
Primary completion
2030-06
later than 247 of 272 live
Registered
1,517th of 1,545
by date

Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 114th largest by planned enrollment of the 1,269 interventional ones that give a count, is one of 39 that started in 2026, is one of 500 in phase 1, reaches primary completion later than 247 of the 272 other live ones, and was the 1,517th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

168 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:

162 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: Up to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevention following matched sibling donor (MSD) or haploidentical (haplo) hematopoietic cell transplantation (HCT) in patients with hematologic malignancies.

We hypothesize that pro-DLI-X will demonstrate safety and superior efficacy by enhancing graft-versus-leukemia (GvL) effects mediated by natural killer (NK) cells, γδ T cells, and CD8+ T cells, while maintaining manageable and treatment-responsive graft-versus-host disease (GvHD).

03

Conditions studied

  • Acute Lymphoid Leukemia
  • Acute Myeloid Leukemia
  • Acute Undifferentiated Leukemia (AUL)
  • Myelodysplastic Syndrome
  • Chronic Myeloid Leukemia
  • Non-Hodgkin Lymphoma

Keywords

  • Exercise
  • Donor Lymphocyte Infusion
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Hematologic Malignancies
  • Matched Sibling Donor
  • Haploidentical
  • Hematopoietic Cell Transplantation
  • DLI-X
04

Who can participate

The criteria were revised on the registry on Oct 22, 2026. See what changed

Ages eligible
Up to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DLI Recipient Inclusion Criteria:

  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 0-65 years
  • Diagnosis of acute leukemia (lymphoid, myeloid or undifferentiated) myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) or non-Hodgkin's lymphoma (NHL)
  • Undergoing myeloablative or reduced intensity matched sibling donor (MSD) HCT or haploidentical HCT
  • Have a locally available healthy matched or haploidentical (≥5/10 HLA antigen matched) related donor between 12 and 50 years of age, consented and able to perform the exercise sessions. (see donor inclusion criteria)

DLI Donor Inclusion Criteria:

  • Provision of signed and dated informed consent form
  • Must have already met transplant donor eligibility as a matched sibling donor, or HLA-haploidentical relative of the patient, including biological parents, siblings, or children, half-siblings, cousins or aunts and uncles
  • Weight is greater than 30 kg
  • Age 12 and 50 years
  • Ability to undergo phlebotomy
  • Be able complete the fitness evaluation to determine VO2max and peak cycling power. Following successful completion of the donor fitness evaluation, the patients willing to participate in the randomized trial will be enrolled
  • Donor's recipient has met eligibility requirements and agreed to participate

DLI Recipient Exclusion Criteria:

  • Acute grade II-IV aGvHD or moderate/severe chronic GvHD at time of scheduled DLI.
  • Requiring therapy for treatment of GvHD.
  • Co-morbidities: /ALT greater than 5 x ; greater than 2 x ULN; Creatinine greater than 2 x ULN for age or / \<40 ml/min/1.73m2; Pulmonary function: DLCO less than 40% of normal or O2 Sat less than 92%; Cardiac: less than 35%; active infection; positive; score (adults) less than 60% or Lansky score less than 50% (pediatrics)
  • Uncontrolled or severe bacterial, fungal or viral infection.
  • Positive serum or urine pregnancy test for girls post menarche or women of childbearing age.
  • Severe psychiatric illness or mental deficiency making compliance to treatment unlikely and/or and/or would preclude informed consent according to IRB requirements for the study.
  • Any reason, at the investigator's discretion, that the participation of the patient in this protocol would not be in patient's best interest, or where the patient would be unable to adhere to the study requirements.

DLI Donor Exclusion Criteria:

  • Unable to perform graded exercise test
  • Cardiac or pulmonary disease/condition that would restrict exercise
  • Positive anti-donor HLA antibody
  • Pregnant or lactating
  • Active infection
  • Severe psychiatric illness or mental deficiency making compliance with donation unlikely and/or would preclude informed consent according to IRB requirements for the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Prophylactic DLI-X Arm

    Conduct the first-in-human, randomized clinical trial comparing prophylactic exercise mobilized donor lymphocyte infusion (pro-DLI-X) with standard (non exercise mobilized) prophylactic DLI (pro-DLI) for relapse prevention following allogeneic hematopoietic cell transplantation (alloHCT) in patients with myeloid or lymphoid malignancies. Patients on this arm will receive pro-DLI-X.

    Biological: Exercise Mobilized Prophylactic DLI

  • Active comparator
    Prophylactic Standard DLI Arm

    Conduct the first-in-human, randomized clinical trial comparing prophylactic exercise mobilized donor lymphocyte infusion (pro-DLI-X) with standard (non exercise mobilized) prophylactic DLI (pro-DLI) for relapse prevention following allogeneic hematopoietic cell transplantation (alloHCT) in patients with myeloid or lymphoid malignancies. Patients on this arm will receive standard DLI-X.

    Biological: Standard Prophylactic DLI

Interventions

  • BiologicalExercise Mobilized Prophylactic DLI

    Pro-DLI-X will be given through the patient's central line at an initial dose of 100,000 CD3+ cells/kilogram (kg) of recipient weight for haploidentical hematopoietic cell transplantation (haploHCT) and 300,000 CD3+ cells/kg for matched sibling donor hematopoietic cell transplantation (MSD HCT). Participants will receive up to 3 doses of pro-DLI-X, and each dose will be increased as follows: dose 2 will be 300,000 CD3+ cells/kg for haploHCT and 1,000,000 CD3+ cells/kg for MSD HCT; dose 3 will be 1,000,000 CD3+ cells/kg for haploHCT and 3,000,000 CD3+ cells/kg for MSD HCT.

    Also known as: pro-DLI-X

  • BiologicalStandard Prophylactic DLI

    Pro-DLI will be given through the patient's central line at an initial dose of 100,000 CD3+ cells/kilogram (kg) of recipient weight for haploidentical hematopoietic cell transplantation (haploHCT) and 300,000 CD3+ cells/kg for matched sibling donor hematopoietic cell transplantation (MSD HCT). Participants will receive up to 3 doses of pro-DLI-X, and each dose will be increased as follows: dose 2 will be 300,000 CD3+ cells/kg for haploHCT and 1,000,000 CD3+ cells/kg for MSD HCT; dose 3 will be 1,000,000 CD3+ cells/kg for haploHCT and 3,000,000 CD3+ cells/kg for MSD HCT.

    Also known as: pro-DLI

06

What researchers measure

Primary outcomes

  1. Prophylactic endpoint: Graft-versus-Host Disease-Free, Relapse-Free Survival (GRFS)

    Graft-versus-Host Disease-Free, Relapse-Free Survival (GRFS) is defined as survival without evidence of disease relapse or grade III-IV acute graft-versus-host-disease (aGvHD) or chronic graft-versus-host-disease (cGvHD) requiring systemic therapy. In essence, GRFS serves as a meaningful measure encompassing not only survival but quality of life. GRFS will be compared in patients randomized to pro-DLI-X versus standard pro-DLI control group.

    Time frame: Assess between 1 to 3 years post HCT

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jun 2030, 43 months after the start.

Of 158 non-industry phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 92. This study's planned 43 months is below that.

Counting every sponsor, half of 208 studies reached it within 55 months; a quarter within 34 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 28, 2025
StartActual
Oct 26, 2026
Primary completionEst.
Jun 1, 2030
CompletionEst.
Jun 1, 2030
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 29, 2026
Sites
The University of Arizona Cancer Center is now Recruiting
Oct 29, 2026
Start date
Oct 31, 2026→Oct 26, 2026 (actual)
moved 2 times, Oct 22, 2026 – Oct 29, 2026
Enrollment
94→180
Oct 22, 2026
Eligibility
6 criteria edited, 2 added, 4 removed
What changed in the criteria
  • RemovedThe familial donors will first complete the fitness evaluation to determine VO2max and peak cycling power and following successful completion of the donor evaluation, the patients willing to participate in the randomized trial will be enrolled.
  • AddedProvision of signed and dated informed consent form
  • EditedMatchedMust have already met transplant donor eligibility as a matched sibling donor, or HLA-haploidentical relativesrelative of the patient, including biological parents, siblings, or children, half-siblings, cousins or aunts and uncles
  • RemovedCardiac, renal, pulmonary, and hepatic function within normal limits
  • RemovedComplete blood count (CBC) with differential and platelet count within normal limits, and CMP within normal limits as deemed acceptable by the Principal Investigator and provider evaluating donor.
  • EditedThe familial donors should beBe able complete the fitness evaluation to determine VO2max and peak cycling power and following. Following successful completion of the donor fitness evaluation, the patients willing to participate in the randomized trial will be enrolled.
  • AddedDonor's recipient has met eligibility requirements and agreed to participate
  • EditedAcute grade IIIII-IV aGvHD or moderate/severe chronic GvHD at time of scheduled DLI.
  • EditedSevere psychiatric illness or mental deficiency making compliance to treatment unlikely and/or and/or would preclude informed consent impossibleaccording to IRB requirements for the study.
  • EditedCardiac or pulmonary disease restricting/condition that would restrict exercise
  • RemovedPositivity for HIV, hepatitis B (HBV), hepatitis C (HCV), human T-cell lymphotropic virus (HTLV-I/II)
  • EditedSevere psychiatric illness or mental deficiency making compliance with donation unlikely and/or would preclude informed consent impossibleaccording to IRB requirements for the study.
Oct 22, 2026
Interventions
Removed Biological: Exercise Mobilized Therapeutic DLI·Biological: Standard Therapeutic DLI. Arm changed Prophylactic Arm→Prophylactic Standard DLI Arm. Arms added: Prophylactic DLI-X Arm; arms removed: Therapeutic Arm
Oct 22, 2026
Primary outcomes
1 removed
What changed in the outcomes
  • RemovedTherapeutic endpoint: Disease response to t-DLI versus t-DLI-X (relapse and GvHD rates as a composite endpoint)Time frame: Assess between 1-3 years post HCT
Oct 22, 2026
Title
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
Oct 22, 2026
Show all 2 updates
  1. Oct 29, 2026
    Not yet recruiting→Recruiting
    The University of Arizona Cancer Center is now Recruiting
    Start date Nov 30, 2026→Oct 26, 2026 (now actual)
  2. Oct 22, 2026
    Start date Oct 31, 2026→Nov 30, 2026
    Enrollment 94→180
    Eligibility 6 criteria edited, 2 added, 4 removed
    What changed in the criteria
    • RemovedThe familial donors will first complete the fitness evaluation to determine VO2max and peak cycling power and following successful completion of the donor evaluation, the patients willing to participate in the randomized trial will be enrolled.
    • AddedProvision of signed and dated informed consent form
    • EditedMatchedMust have already met transplant donor eligibility as a matched sibling donor, or HLA-haploidentical relativesrelative of the patient, including biological parents, siblings, or children, half-siblings, cousins or aunts and uncles
    • RemovedCardiac, renal, pulmonary, and hepatic function within normal limits
    • RemovedComplete blood count (CBC) with differential and platelet count within normal limits, and CMP within normal limits as deemed acceptable by the Principal Investigator and provider evaluating donor.
    • EditedThe familial donors should beBe able complete the fitness evaluation to determine VO2max and peak cycling power and following. Following successful completion of the donor fitness evaluation, the patients willing to participate in the randomized trial will be enrolled.
    • AddedDonor's recipient has met eligibility requirements and agreed to participate
    • EditedAcute grade IIIII-IV aGvHD or moderate/severe chronic GvHD at time of scheduled DLI.
    • EditedSevere psychiatric illness or mental deficiency making compliance to treatment unlikely and/or and/or would preclude informed consent impossibleaccording to IRB requirements for the study.
    • EditedCardiac or pulmonary disease restricting/condition that would restrict exercise
    • RemovedPositivity for HIV, hepatitis B (HBV), hepatitis C (HCV), human T-cell lymphotropic virus (HTLV-I/II)
    • EditedSevere psychiatric illness or mental deficiency making compliance with donation unlikely and/or would preclude informed consent impossibleaccording to IRB requirements for the study.
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedTherapeutic endpoint: Disease response to t-DLI versus t-DLI-X (relapse and GvHD rates as a composite endpoint)Time frame: Assess between 1-3 years post HCT
    Interventions Removed Biological: Exercise Mobilized Therapeutic DLI·Biological: Standard Therapeutic DLI. Arm changed Prophylactic Arm→Prophylactic Standard DLI Arm. Arms added: Prophylactic DLI-X Arm; arms removed: Therapeutic Arm
    Title Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07254793
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Oct 26, 2026
Primary completion
Jun 1, 2030 (estimated)
Completion
Jun 1, 2030 (estimated)
Last update
Oct 29, 2026

Study contacts

Michele Chu-Pilli
Contact
chum@arizona.edu
520-626-1183
Emmanuel Katsanis, MD
principal investigator · University of Arizona

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion